Akero Therapeutics 과거 수익 실적

과거 기준 확인 0/6

Akero Therapeutics의 수입은 연평균 -24.9%의 비율로 감소해 온 반면, Biotechs 산업의 수입은 연간 증가했습니다(19.3%).

주요 정보

-24.9%

수익 성장률

8.7%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	n/a
자기자본 수익률	-32.1%
순이익	n/a
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

업데이트 없음

Recent updates

수익 및 비용 분석

Akero Therapeutics 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGS:AKRO 수익, 비용 및 수입 (USD Millions )
날짜	수익	G+A 비용	R&D 비용
30 Sep 24	-237	38	232
30 Jun 24	-204	36	198
31 Mar 24	-179	33	171
31 Dec 23	-152	31	142
30 Sep 23	-120	30	107
30 Jun 23	-116	33	93
31 Mar 23	-112	31	87
31 Dec 22	-112	30	85
30 Sep 22	-121	28	95
30 Jun 22	-110	21	89
31 Mar 22	-112	20	92
31 Dec 21	-101	19	82
30 Sep 21	-98	18	80
30 Jun 21	-95	18	78
31 Mar 21	-82	16	67
31 Dec 20	-79	15	65
30 Sep 20	-65	14	52
30 Jun 20	-59	13	49
31 Mar 20	-50	11	42
31 Dec 19	-44	9	37
30 Sep 19	-90	7	26
30 Jun 19	-86	5	13
31 Mar 19	-87	3	16
31 Dec 18	-82	2	12
30 Sep 18	-22	1	11

양질의 수익: AKRO 은(는) 현재 수익성이 없습니다.

이익 마진 증가: AKRO 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: AKRO 은(는) 수익성이 없으며 지난 5년 동안 연간 24.9% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 AKRO 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: AKRO 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 16.6% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: AKRO 현재 수익성이 없기 때문에 마이너스 자본 수익률( -32.13% )을 갖습니다.

Akero Therapeutics 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Recent updates

Akero Therapeutics, Inc. to Showcase New Analyses of Phase 2b Harmony Study in Presentations at 75th Annual AASLD The Liver Meeting®? 2024

Akero Therapeutics, Inc. Provides Business Update

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Akero Therapeutics: Good Candidate For The MASH Basket

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

New major risk - Revenue and earnings growth

Executive VP notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

Insufficient new directors

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc

Co-Founder notifies of intention to sell stock

Akero Therapeutics' EFX Data Warrants Caution

Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

President notifies of intention to sell stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

Price target increased by 13% to US$48.38

Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Akero Therapeutics, Inc. Announces First Patients Dosed in Efruxifermin Phase 3 Synchrony Program

President exercised options and sold US$368k worth of stock

Co-Founder recently sold US$440k worth of stock

Price target decreased by 29% to US$48.44

Akero Therapeutics, Inc. Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

New major risk - Share price stability

Akero Therapeutics, Inc. to Present Results from Phase 2B Symmetry Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Akero Therapeutics, Inc. Announces Publication of the Harmony Phase 2B Trial Results in the Lancet Gastroenterology & Hepatology

President notifies of intention to sell stock

Price target increased by 7.3% to US$67.75

Price target increased by 7.7% to US$64.75

Insider notifies of intention to sell stock

Akero Therapeutics, Inc. to Report Results of Phase 2b SYMMETRY Study in October 2023

President exercised options and sold US$920k worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from Russell Small Cap Comp Value Index

Co-Founder & Chief Scientific Officer recently sold US$2.1m worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

President exercised options and sold US$1.1m worth of stock

Akero Therapeutics, Inc. Releases Topline Data from an Expansion Cohort of the Phase 2B SYMMETRY Study

President exercised options and sold US$1.1m worth of stock

President notifies of intention to sell stock

President exercised options and sold US$1.2m worth of stock

President exercised options and sold US$1.2m worth of stock

Insider notifies of intention to sell stock

Akero Therapeutics, Inc. Announces the Appointment of Patrick Lamy as Senior Vice President, Commercial Strategy

Co-Founder exercised options and sold US$544k worth of stock

Price target increased to US$52.00

Akero Therapeutics, Inc. Completes Enrollment of Phase 2B SYMMETRY Study

President exercised options and sold US$455k worth of stock

Independent Director recently sold US$1.1m worth of stock

President exercised options and sold US$428k worth of stock

Independent Director recently sold US$12m worth of stock

Price target increased to US$48.33

Co-Founder & Chief Scientific Officer exercised options and sold US$299k worth of stock

Akero Therapeutics announces closing of upsized public offering

President notifies of intention to sell stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. Releases Topline Data from HARMONY

Akero adds over 100% rallying peers after NASH success

Akero Therapeutics, Inc. Announces Results from Cohort C of its Phase 2a BALANCED trial in non-alcoholic steatohepatitis

Price target decreased to US$41.67

Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis

Akero Therapeutics, Inc. announced that it expects to receive $100 million in funding from Hercules Capital, Inc.

High number of new directors

We're Not Very Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Rate

High number of new directors

President exercised options and sold US$170k worth of stock